6:32 PM
 | 
May 16, 2013
 |  BC Extra  |  Clinical News

Oncothyreon off after Phase II data for PX-866

Oncothyreon Inc. (NASDAQ:ONTY) fell $0.64 (25%) to $1.97 on Thursday after reporting data from two Phase II trials of once-daily oral PX-866 to treat recurrent glioblastoma multiforme (GBM) and recurrent or metastatic castration-resistant prostate cancer (CRPC). In 33 evaluable...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >